Status:
COMPLETED
Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes
Lead Sponsor:
Intarcia Therapeutics
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
30-70 years
Phase:
PHASE1
Brief Summary
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.
Eligibility Criteria
Inclusion
- type 2 diabetes \>6 months
- stable diet \& exercise, metformin, TZD or met + TZD HbA1c \>6.5% \<10.0%
Exclusion
- prior treatment with exenatide
- history of pancreatitis
- history of medullary thyroid cancer or multiple endocrine neoplasia 2
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01798264
Start Date
February 1 2009
End Date
May 1 2009
Last Update
May 17 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Miami Gardens, Florida, United States, 33169
2
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States, 45212
3
dGd Research
San Antonio, Texas, United States, 78229